Foscarnet (phosphonomethanoic acid), known by its brand name Foscavir, is an antiviral medication which is primarily used to treat viral infections involving the Herpesviridae family. It is classified as a pyrophosphate analog DNA polymerase inhibitor.[3][4] Foscarnet is the conjugate base of a chemical compound with the formulaHO2CPO3H2 (Trisodium phosphonoformate).[5][6]
Clinical data | |
---|---|
Trade names | Foscavir, Vocarvi, others |
Other names | phosphonomethanoic acid, dihydroxyphosphinecarboxylic acid oxide |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601144 |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | NA |
Protein binding | 14–17% |
Elimination half-life | 3.3–6.8 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | CH3O5P |
Molar mass | 126.004 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Foscarnet was approved for medical use in 1991.[7] It is available as a generic medication.[8]
This phosphonic acid derivative (marketed by Clinigen as foscarnet sodium under the trade name Foscavir) is an antiviral medication used to treat herpes viruses, including drug-resistant cytomegalovirus (CMV) and herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2). It is particularly used to treat CMV retinitis. Foscarnet can be used to treat highly treatment-experienced patients with HIV as part of salvage therapy.[9][10][11]
Foscarnet is a structural mimic of the anion pyrophosphate that selectively inhibits the pyrophosphate binding site on viral DNA polymerasesatconcentrations that do not affect human DNA polymerases.[11]
In individuals treated with the DNA polymerase inhibitors acyclovirorganciclovir, HSV or CMV particles can develop mutant protein kinases (thymidine kinase or UL97 protein kinase, respectively) that make them resistant to these antiviral drugs.[12][13] However, unlike acyclovir and ganciclovir, foscarnet is not activated by viral protein kinases, making it useful in acyclovir- or ganciclovir-resistant HSV and CMV infections.[5]
However, acyclovir- or ganciclovir-resistant mutants with alterations in viral DNA polymerase may also be resistant to foscarnet.[14][15]
Foscarnet is administered by intravenous infusion or intravitreous injection.[citation needed]